9 Meters Biopharma, Inc. (NMTR)

NASDAQ: NMTR · IEX Real-Time Price · USD
0.264
0.000 (-0.15%)
At close: Aug 11, 2022 4:00 PM
0.271
+0.007 (2.727%)
Pre-market: Aug 12, 2022 8:29 AM EDT
-0.15%
Market Cap 71.96M
Revenue (ttm) n/a
Net Income (ttm) -42.70M
Shares Out 272.58M
EPS (ttm) -0.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,972,762
Open 0.265
Previous Close 0.264
Day's Range 0.254 - 0.272
52-Week Range 0.197 - 1.460
Beta 0.49
Analysts Buy
Price Target 3.32 (+1,157.6%)
Earnings Date Aug 11, 2022

About NMTR

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short ... [Read more...]

Industry Pharmaceuticals
Founded 2012
CEO Sandeep Laumas
Employees 21
Stock Exchange NASDAQ
Ticker Symbol NMTR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for NMTR stock is "Buy." The 12-month stock price forecast is 3.32, which is an increase of 1,157.58% from the latest price.

Price Target
$3.32
(1,157.58% upside)
Analyst Consensus: Buy
Stock Forecasts

News

9 Meters Biopharma to Participate in the William Blair Biotech Focus Conference 2022

RALEIGH, NC / ACCESSWIRE / July 6, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced ...

9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome

Initial Draw of $20 Million to Support Funding Phase 3 Development of Vurolenatide in Short Bowel Syndrome RALEIGH, NC / ACCESSWIRE / June 30, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-s...

9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome

Phase 2 VIBRANT study identifies a dose and dosing interval with >25% improvement in the primary endpoint of 24-hour mean total stool output reduction over 6 weeks Vurolenatide was generally well tolera...

Why Are 9 Meters Biopharma Shares Plunging Today?

9 Meters Biopharma Inc (NASDAQ: NMTR) completed a pre-specified interim analysis for the Phase 3 study of larazotide for patients with celiac disease who continue to experience gastrointestinal symptoms...

9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Tria...

Additional analyses to determine if a subgroup of patients and/or symptoms may have been responsive to treatment Company remains on track to deliver vurolenatide Phase 2 short bowel syndrome results by ...

9 Meters Biopharma to Participate in the 2022 BIO International Convention

RALEIGH, NC / ACCESSWIRE / June 13, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced...

9 Meters Biopharma to Exhibit at Digestive Disease Week 2022

RALEIGH, NC / ACCESSWIRE / May 19, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced ...

9 Meters Biopharma Presents Preclinical Data at the 2022 American Thoracic Society International Conference on the Us...

RALEIGH, NC / ACCESSWIRE / May 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced ...

9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2022

On track to report Phase 2 data for vurolenatide for short bowel syndrome and Phase 3 interim analysis for celiac disease in June Cash balance as of March 31, 2022, of $37.2 million is expected to fund ...

9 Meters Biopharma to Present at the H.C. Wainwright Global Investment Conference and the LifeSci Partners Immunology...

RALEIGH, NC / ACCESSWIRE / May 5, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced t...

9 Meters Biopharma and Celiac.com Announce Collaboration to Support Clinical Trial Enrollment in 9 Meter's Phase 3 St...

RALEIGH, NC and SANTA ROSA, CA / ACCESSWIRE / April 20, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive...

9 Meters Biopharma Announces Allowance of Patent for Anti-GIP Monoclonal Antibody NM-136 for the Treatment of Serious...

RALEIGH, NC / ACCESSWIRE / April 13, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announce...

9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2021

RALEIGH, NC / ACCESSWIRE / March 23, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today pr...

9 Meters Biopharma to Present at the Maxim Group 2022 Virtual Growth Conference

RALEIGH, NC / ACCESSWIRE / March 21, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announce...

9 Meters Biopharma to Present at the Oppenheimer 32nd Annual Healthcare Conference

RALEIGH, NC / ACCESSWIRE / March 9, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced...

9 Meters Biopharma Announces a Collaboration with NYU Langone Health Investigating NM-102 as a Potential Treatment fo...

RALEIGH, NC / ACCESSWIRE / March 2, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced...

9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and...

RALEIGH, NC / ACCESSWIRE / February 28, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, annou...

9 Meters Biopharma Announces Publication of Data on Larazotide for the Treatment of Multisystem Inflammatory Syndrome...

RALEIGH, NC / ACCESSWIRE / February 25, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, annou...

9 Meters Biopharma to Present at the 2022 BIO CEO & Investor Conference

RALEIGH, NC / ACCESSWIRE / February 9, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases announc...

9 Meters Biopharma Announces Allowance of Patent for NM-102 in Combination with Immune Checkpoint Inhibitors

RALEIGH, NC / ACCESSWIRE / January 24, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announ...

9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer

Formerly served as VP of Finance and Commercial Operations at Biogen with 20+ years of business and strategic financial leadership experience RALEIGH, NC / ACCESSWIRE / January 18, 2022 / 9 Meters Bioph...

9 Meters Biopharma, Inc. to Participate in the following Virtual January Investor Conferences

RALEIGH, NC / ACCESSWIRE / January 4, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive d...

9 Meters Biopharma Appoints Sarah Liu as Chief Commercial Officer and Al Medwar as Senior Vice President of Investor ...

RALEIGH, NC / ACCESSWIRE / January 3, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR),a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studyi...

9 Meters Biopharma, Inc. Awards Unrestricted Educational Grant Funding to Carol Rees Parrish, M.S., RDN, for Short Bo...

RALEIGH, NC / ACCESSWIRE / December 15, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive...

Down 20.5% in 4 Weeks, Here's Why You Should You Buy the Dip in 9 Meters Biopharma, Inc. (NMTR)

The heavy selling pressure might have exhausted for 9 Meters Biopharma, Inc. (NMTR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Str...